Enliven Therapeutics, Inc. Common Stock

Enliven Therapeutics, Inc. Common Stock

Compare this stock

ELVN Stock Report Card

$

VolatilityProfitPerformanceEarnings

15%

Performance

Score:

10/100

ELVN returned -54.38% in the last 12 months. Based on SPY's performance of -13.00%, its performance is below average giving it a score of 10 of 100.

Earnings

Score:

10/100

ELVN has missed earnings 12 times in the last 20 quarters.

Profit

Score:

10/100

Out of the last 19 quarters, ELVN has had 1 profitable quarters and has increased their profits year over year on 1 of them.

Volatility

Score:

47/100

ELVN has had a lower than average amount of volatility over the last 12 months giving it a score of 46 of 100.

Enliven Therapeutics, Inc. Common Stock Summary

Nasdaq / ELVN
Healthcare
Biotechnology
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.